Catalyst Wire Dossier Catalyst Wire Dossier

CNTO 1959 (guselkumab)

guselkumab · Janssen Biotech, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CNTO 1959 (guselkumab), covering 2015-11-20 to 2015-11-20. Get the full timeline:

Most recent: Clinical Trial Update: A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis [Phase 2]

See pricing